AU Patent

AU2013203111B2 — Methods for treating cancer resistant to erbb therapeutics

Assigned to General Hospital Corp · Expires 2015-10-08 · 11y expired

What this patent protects

Provided herein are methods for treating cancer that is resistant to treatment with an anti- ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene 5 amplification. The methods involve administering to a subject a combination of an anti-…

USPTO Abstract

Provided herein are methods for treating cancer that is resistant to treatment with an anti- ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene 5 amplification. The methods involve administering to a subject a combination of an anti- ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or P13 kinase mediated signaling in a cancer cell.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013203111B2
Jurisdiction
AU
Classification
—
Expires
2015-10-08
Drug substance claim
No
Drug product claim
No
Assignee
General Hospital Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.